Neutrophil Gelatinase-Associated Lipocalin, a Novel Mineralocorticoid Biotarget, Mediates Vascular Profibrotic Effects of Mineralocorticoids.
Identifieur interne : 000754 ( Main/Exploration ); précédent : 000753; suivant : 000755Neutrophil Gelatinase-Associated Lipocalin, a Novel Mineralocorticoid Biotarget, Mediates Vascular Profibrotic Effects of Mineralocorticoids.
Auteurs : Antoine Tarjus [France] ; Ernesto Martínez-Martínez [France] ; Cristian Amador [France] ; Céline Latouche [France] ; Soumaya El Moghrabi [France] ; Thorsten Berger [France] ; Tak W. Mak [France] ; Renaud Fay [France] ; Nicolette Farman [France] ; Patrick Rossignol [France] ; Faiez Zannad [France] ; Natalia L Pez-Andrés [France] ; Frédéric Jaisser [France]Source :
- Hypertension [ 1524-4563 ] ; 2015.
Descripteurs français
- KwdFr :
- Aldostérone (sang), Aldostérone (toxicité), Animaux, Aorte (), Aorte (anatomopathologie), Cardiomyopathie hypertrophique (), Cardiomyopathie hypertrophique (physiopathologie), Cellules cultivées, Cytokines (biosynthèse), Cytokines (génétique), Femelle, Fibroblastes, Fibrose, Fragments peptidiques (sang), Galectine -3 (biosynthèse), Galectine -3 (génétique), Galectine -3 (sang), Humains, Hypertension artérielle (physiopathologie), Hypertrophie, Lipocalines (génétique), Lipocalines (pharmacologie), Lipocalines (physiologie), Lipocalines (sang), Myocarde (cytologie), Myocarde (métabolisme), Myocytes du muscle lisse (), Myocytes du muscle lisse (physiologie), Mâle, Néphrectomie (effets indésirables), Obésité abdominale (physiopathologie), Obésité abdominale (sang), Procollagène (sang), Protéine de la phase aigüe (déficit), Protéine de la phase aigüe (génétique), Protéine de la phase aigüe (pharmacologie), Protéine de la phase aigüe (physiologie), Protéines oncogènes (déficit), Protéines oncogènes (génétique), Protéines oncogènes (physiologie), Protéines proto-oncogènes (pharmacologie), Protéines proto-oncogènes (physiologie), Protéines proto-oncogènes (sang), Protéines recombinantes (pharmacologie), Rats, Rein (anatomopathologie), Souris.
- MESH :
- anatomopathologie : Aorte, Rein.
- biosynthèse : Cytokines, Galectine -3.
- cytologie : Myocarde.
- déficit : Protéine de la phase aigüe, Protéines oncogènes.
- effets indésirables : Néphrectomie.
- génétique : Cytokines, Galectine -3, Lipocalines, Protéine de la phase aigüe, Protéines oncogènes.
- métabolisme : Myocarde.
- pharmacologie : Lipocalines, Protéine de la phase aigüe, Protéines proto-oncogènes, Protéines recombinantes.
- physiologie : Lipocalines, Myocytes du muscle lisse, Protéine de la phase aigüe, Protéines oncogènes, Protéines proto-oncogènes.
- physiopathologie : Cardiomyopathie hypertrophique, Hypertension artérielle, Obésité abdominale.
- sang : Aldostérone, Fragments peptidiques, Galectine -3, Lipocalines, Obésité abdominale, Procollagène, Protéines proto-oncogènes.
- toxicité : Aldostérone.
- Animaux, Aorte, Cardiomyopathie hypertrophique, Cellules cultivées, Femelle, Fibroblastes, Fibrose, Humains, Hypertrophie, Myocytes du muscle lisse, Mâle, Rats, Souris.
English descriptors
- KwdEn :
- Acute-Phase Proteins (deficiency), Acute-Phase Proteins (genetics), Acute-Phase Proteins (pharmacology), Acute-Phase Proteins (physiology), Aldosterone (blood), Aldosterone (toxicity), Animals, Aorta (drug effects), Aorta (pathology), Cardiomyopathy, Hypertrophic (chemically induced), Cardiomyopathy, Hypertrophic (physiopathology), Cells, Cultured, Cytokines (biosynthesis), Cytokines (genetics), Female, Fibroblasts, Fibrosis, Galectin 3 (biosynthesis), Galectin 3 (blood), Galectin 3 (genetics), Humans, Hypertension (physiopathology), Hypertrophy, Kidney (pathology), Lipocalins (blood), Lipocalins (genetics), Lipocalins (pharmacology), Lipocalins (physiology), Male, Mice, Myocardium (cytology), Myocardium (metabolism), Myocytes, Smooth Muscle (drug effects), Myocytes, Smooth Muscle (physiology), Nephrectomy (adverse effects), Obesity, Abdominal (blood), Obesity, Abdominal (physiopathology), Oncogene Proteins (deficiency), Oncogene Proteins (genetics), Oncogene Proteins (physiology), Peptide Fragments (blood), Procollagen (blood), Proto-Oncogene Proteins (blood), Proto-Oncogene Proteins (pharmacology), Proto-Oncogene Proteins (physiology), Rats, Recombinant Proteins (pharmacology).
- MESH :
- chemical , biosynthesis : Cytokines, Galectin 3.
- chemical , blood : Aldosterone, Galectin 3, Lipocalins, Peptide Fragments, Procollagen, Proto-Oncogene Proteins.
- chemical , deficiency : Acute-Phase Proteins, Oncogene Proteins.
- chemical , genetics : Acute-Phase Proteins, Cytokines, Galectin 3, Lipocalins, Oncogene Proteins.
- chemical , pharmacology : Acute-Phase Proteins, Lipocalins, Proto-Oncogene Proteins, Recombinant Proteins.
- chemical , physiology : Acute-Phase Proteins, Lipocalins, Oncogene Proteins, Proto-Oncogene Proteins.
- chemical , toxicity : Aldosterone.
- adverse effects : Nephrectomy.
- blood : Obesity, Abdominal.
- chemically induced : Cardiomyopathy, Hypertrophic.
- cytology : Myocardium.
- drug effects : Aorta, Myocytes, Smooth Muscle.
- metabolism : Myocardium.
- pathology : Aorta, Kidney.
- physiology : Myocytes, Smooth Muscle.
- physiopathology : Cardiomyopathy, Hypertrophic, Hypertension, Obesity, Abdominal.
- Animals, Cells, Cultured, Female, Fibroblasts, Fibrosis, Humans, Hypertrophy, Male, Mice, Rats.
Abstract
Activation of the mineralocorticoid receptor has been shown to be deleterious in cardiovascular diseases (CVDs). We have recently shown that lipocalin 2 (Lcn2), or neutrophil gelatinase-associated lipocalin (NGAL), is a primary target of aldosterone/mineralocorticoid receptor in the cardiovascular system. Lcn2 is a circulating protein, which binds matrix metalloproteinase 9 and modulates its stability. We hypothesized that Lcn2 could be a mediator of aldosterone/mineralocorticoid receptor profibrotic effects in the cardiovascular system. Correlations between aldosterone and profibrotic markers, such as procollagen type I N-terminal peptide, were investigated in healthy subjects and subjects with abdominal obesity. The implication of Lcn2 in the mineralocorticoid pathway was studied using Lcn2 knockout mice subjected to a nephrectomy/aldosterone/salt (NAS) challenge for 4 weeks. In human subjects, NGAL/matrix metalloproteinase 9 was positively correlated with plasma aldosterone and fibrosis biomarkers. In mice, loss of Lcn2 prevented the NAS-induced increase of plasma procollagen type I N-terminal peptide, as well as the increase of collagen fibers deposition and collagen I expression in the coronary vessels and the aorta. The lack of Lcn2 also blunted the NAS-induced increase in systolic blood pressure. Ex vivo, treatment of human fibroblasts with recombinant Lcn2 induced the expression of collagen I and the profibrotic galectin-3 and cardiotrophin-1 molecules. Our results showed that Lcn2 plays a key role in aldosterone/mineralocorticoid receptor-mediated vascular fibrosis. The clinical data indicate that this may translate in human patients. Lcn2 is, therefore, a new biotarget in cardiovascular fibrosis induced by mineralocorticoid activation.
DOI: 10.1161/HYPERTENSIONAHA.115.05431
PubMed: 25987661
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000053
- to stream PubMed, to step Curation: 000053
- to stream PubMed, to step Checkpoint: 000044
- to stream Ncbi, to step Merge: 000190
- to stream Ncbi, to step Curation: 000183
- to stream Ncbi, to step Checkpoint: 000183
- to stream Main, to step Merge: 000743
- to stream Main, to step Curation: 000754
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Neutrophil Gelatinase-Associated Lipocalin, a Novel Mineralocorticoid Biotarget, Mediates Vascular Profibrotic Effects of Mineralocorticoids.</title><author><name sortKey="Tarjus, Antoine" sort="Tarjus, Antoine" uniqKey="Tarjus A" first="Antoine" last="Tarjus">Antoine Tarjus</name><affiliation wicri:level="4"><nlm:affiliation>From the INSERM UMR 1138 Team 1, Centre de Recherche des Cordeliers, Université Pierre et Marie Curie, Paris, France (A.T., C.A., C.L., S.E.M., N.F., F.J.); NAVARRABIOMED-FUNDACIÓN MIGUEL SERVET, Pamplona, Spain (E.M.-M., N.L.-A.); The Campbell Family Institute for Cancer Research, University Health Network, Toronto, ON, Canada (T.B., T.W.M.); INSERM, Centre d'Investigations Cliniques-Plurithématique 1433, CHU de Nancy, France (R.F., P.R., F.Z., N.L.-A., F.J.); Université de Lorraine, Nancy, France (R.F., P.R., F.Z., N.L.-A., F.J.); and INI-CRCT F-CRIN, Nancy, France (R.F., P.R., F.Z., N.L.-A., F.J.).</nlm:affiliation><orgName type="university">Université Pierre-et-Marie-Curie</orgName><country>France</country><placeName><settlement type="city">Paris</settlement><region type="region" nuts="2">Île-de-France</region></placeName></affiliation></author><author><name sortKey="Martinez Martinez, Ernesto" sort="Martinez Martinez, Ernesto" uniqKey="Martinez Martinez E" first="Ernesto" last="Martínez-Martínez">Ernesto Martínez-Martínez</name><affiliation wicri:level="4"><nlm:affiliation>From the INSERM UMR 1138 Team 1, Centre de Recherche des Cordeliers, Université Pierre et Marie Curie, Paris, France (A.T., C.A., C.L., S.E.M., N.F., F.J.); NAVARRABIOMED-FUNDACIÓN MIGUEL SERVET, Pamplona, Spain (E.M.-M., N.L.-A.); The Campbell Family Institute for Cancer Research, University Health Network, Toronto, ON, Canada (T.B., T.W.M.); INSERM, Centre d'Investigations Cliniques-Plurithématique 1433, CHU de Nancy, France (R.F., P.R., F.Z., N.L.-A., F.J.); Université de Lorraine, Nancy, France (R.F., P.R., F.Z., N.L.-A., F.J.); and INI-CRCT F-CRIN, Nancy, France (R.F., P.R., F.Z., N.L.-A., F.J.).</nlm:affiliation><orgName type="university">Université Pierre-et-Marie-Curie</orgName><country>France</country><placeName><settlement type="city">Paris</settlement><region type="region" nuts="2">Île-de-France</region></placeName></affiliation></author><author><name sortKey="Amador, Cristian" sort="Amador, Cristian" uniqKey="Amador C" first="Cristian" last="Amador">Cristian Amador</name><affiliation wicri:level="4"><nlm:affiliation>From the INSERM UMR 1138 Team 1, Centre de Recherche des Cordeliers, Université Pierre et Marie Curie, Paris, France (A.T., C.A., C.L., S.E.M., N.F., F.J.); NAVARRABIOMED-FUNDACIÓN MIGUEL SERVET, Pamplona, Spain (E.M.-M., N.L.-A.); The Campbell Family Institute for Cancer Research, University Health Network, Toronto, ON, Canada (T.B., T.W.M.); INSERM, Centre d'Investigations Cliniques-Plurithématique 1433, CHU de Nancy, France (R.F., P.R., F.Z., N.L.-A., F.J.); Université de Lorraine, Nancy, France (R.F., P.R., F.Z., N.L.-A., F.J.); and INI-CRCT F-CRIN, Nancy, France (R.F., P.R., F.Z., N.L.-A., F.J.).</nlm:affiliation><orgName type="university">Université Pierre-et-Marie-Curie</orgName><country>France</country><placeName><settlement type="city">Paris</settlement><region type="region" nuts="2">Île-de-France</region></placeName></affiliation></author><author><name sortKey="Latouche, Celine" sort="Latouche, Celine" uniqKey="Latouche C" first="Céline" last="Latouche">Céline Latouche</name><affiliation wicri:level="4"><nlm:affiliation>From the INSERM UMR 1138 Team 1, Centre de Recherche des Cordeliers, Université Pierre et Marie Curie, Paris, France (A.T., C.A., C.L., S.E.M., N.F., F.J.); NAVARRABIOMED-FUNDACIÓN MIGUEL SERVET, Pamplona, Spain (E.M.-M., N.L.-A.); The Campbell Family Institute for Cancer Research, University Health Network, Toronto, ON, Canada (T.B., T.W.M.); INSERM, Centre d'Investigations Cliniques-Plurithématique 1433, CHU de Nancy, France (R.F., P.R., F.Z., N.L.-A., F.J.); Université de Lorraine, Nancy, France (R.F., P.R., F.Z., N.L.-A., F.J.); and INI-CRCT F-CRIN, Nancy, France (R.F., P.R., F.Z., N.L.-A., F.J.).</nlm:affiliation><orgName type="university">Université Pierre-et-Marie-Curie</orgName><country>France</country><placeName><settlement type="city">Paris</settlement><region type="region" nuts="2">Île-de-France</region></placeName></affiliation></author><author><name sortKey="El Moghrabi, Soumaya" sort="El Moghrabi, Soumaya" uniqKey="El Moghrabi S" first="Soumaya" last="El Moghrabi">Soumaya El Moghrabi</name><affiliation wicri:level="4"><nlm:affiliation>From the INSERM UMR 1138 Team 1, Centre de Recherche des Cordeliers, Université Pierre et Marie Curie, Paris, France (A.T., C.A., C.L., S.E.M., N.F., F.J.); NAVARRABIOMED-FUNDACIÓN MIGUEL SERVET, Pamplona, Spain (E.M.-M., N.L.-A.); The Campbell Family Institute for Cancer Research, University Health Network, Toronto, ON, Canada (T.B., T.W.M.); INSERM, Centre d'Investigations Cliniques-Plurithématique 1433, CHU de Nancy, France (R.F., P.R., F.Z., N.L.-A., F.J.); Université de Lorraine, Nancy, France (R.F., P.R., F.Z., N.L.-A., F.J.); and INI-CRCT F-CRIN, Nancy, France (R.F., P.R., F.Z., N.L.-A., F.J.).</nlm:affiliation><orgName type="university">Université Pierre-et-Marie-Curie</orgName><country>France</country><placeName><settlement type="city">Paris</settlement><region type="region" nuts="2">Île-de-France</region></placeName></affiliation></author><author><name sortKey="Berger, Thorsten" sort="Berger, Thorsten" uniqKey="Berger T" first="Thorsten" last="Berger">Thorsten Berger</name><affiliation wicri:level="4"><nlm:affiliation>From the INSERM UMR 1138 Team 1, Centre de Recherche des Cordeliers, Université Pierre et Marie Curie, Paris, France (A.T., C.A., C.L., S.E.M., N.F., F.J.); NAVARRABIOMED-FUNDACIÓN MIGUEL SERVET, Pamplona, Spain (E.M.-M., N.L.-A.); The Campbell Family Institute for Cancer Research, University Health Network, Toronto, ON, Canada (T.B., T.W.M.); INSERM, Centre d'Investigations Cliniques-Plurithématique 1433, CHU de Nancy, France (R.F., P.R., F.Z., N.L.-A., F.J.); Université de Lorraine, Nancy, France (R.F., P.R., F.Z., N.L.-A., F.J.); and INI-CRCT F-CRIN, Nancy, France (R.F., P.R., F.Z., N.L.-A., F.J.).</nlm:affiliation><orgName type="university">Université Pierre-et-Marie-Curie</orgName><country>France</country><placeName><settlement type="city">Paris</settlement><region type="region" nuts="2">Île-de-France</region></placeName></affiliation></author><author><name sortKey="Mak, Tak W" sort="Mak, Tak W" uniqKey="Mak T" first="Tak W" last="Mak">Tak W. Mak</name><affiliation wicri:level="4"><nlm:affiliation>From the INSERM UMR 1138 Team 1, Centre de Recherche des Cordeliers, Université Pierre et Marie Curie, Paris, France (A.T., C.A., C.L., S.E.M., N.F., F.J.); NAVARRABIOMED-FUNDACIÓN MIGUEL SERVET, Pamplona, Spain (E.M.-M., N.L.-A.); The Campbell Family Institute for Cancer Research, University Health Network, Toronto, ON, Canada (T.B., T.W.M.); INSERM, Centre d'Investigations Cliniques-Plurithématique 1433, CHU de Nancy, France (R.F., P.R., F.Z., N.L.-A., F.J.); Université de Lorraine, Nancy, France (R.F., P.R., F.Z., N.L.-A., F.J.); and INI-CRCT F-CRIN, Nancy, France (R.F., P.R., F.Z., N.L.-A., F.J.).</nlm:affiliation><orgName type="university">Université Pierre-et-Marie-Curie</orgName><country>France</country><placeName><settlement type="city">Paris</settlement><region type="region" nuts="2">Île-de-France</region></placeName></affiliation></author><author><name sortKey="Fay, Renaud" sort="Fay, Renaud" uniqKey="Fay R" first="Renaud" last="Fay">Renaud Fay</name><affiliation wicri:level="4"><nlm:affiliation>From the INSERM UMR 1138 Team 1, Centre de Recherche des Cordeliers, Université Pierre et Marie Curie, Paris, France (A.T., C.A., C.L., S.E.M., N.F., F.J.); NAVARRABIOMED-FUNDACIÓN MIGUEL SERVET, Pamplona, Spain (E.M.-M., N.L.-A.); The Campbell Family Institute for Cancer Research, University Health Network, Toronto, ON, Canada (T.B., T.W.M.); INSERM, Centre d'Investigations Cliniques-Plurithématique 1433, CHU de Nancy, France (R.F., P.R., F.Z., N.L.-A., F.J.); Université de Lorraine, Nancy, France (R.F., P.R., F.Z., N.L.-A., F.J.); and INI-CRCT F-CRIN, Nancy, France (R.F., P.R., F.Z., N.L.-A., F.J.).</nlm:affiliation><orgName type="university">Université Pierre-et-Marie-Curie</orgName><country>France</country><placeName><settlement type="city">Paris</settlement><region type="region" nuts="2">Île-de-France</region></placeName></affiliation></author><author><name sortKey="Farman, Nicolette" sort="Farman, Nicolette" uniqKey="Farman N" first="Nicolette" last="Farman">Nicolette Farman</name><affiliation wicri:level="4"><nlm:affiliation>From the INSERM UMR 1138 Team 1, Centre de Recherche des Cordeliers, Université Pierre et Marie Curie, Paris, France (A.T., C.A., C.L., S.E.M., N.F., F.J.); NAVARRABIOMED-FUNDACIÓN MIGUEL SERVET, Pamplona, Spain (E.M.-M., N.L.-A.); The Campbell Family Institute for Cancer Research, University Health Network, Toronto, ON, Canada (T.B., T.W.M.); INSERM, Centre d'Investigations Cliniques-Plurithématique 1433, CHU de Nancy, France (R.F., P.R., F.Z., N.L.-A., F.J.); Université de Lorraine, Nancy, France (R.F., P.R., F.Z., N.L.-A., F.J.); and INI-CRCT F-CRIN, Nancy, France (R.F., P.R., F.Z., N.L.-A., F.J.).</nlm:affiliation><orgName type="university">Université Pierre-et-Marie-Curie</orgName><country>France</country><placeName><settlement type="city">Paris</settlement><region type="region" nuts="2">Île-de-France</region></placeName></affiliation></author><author><name sortKey="Rossignol, Patrick" sort="Rossignol, Patrick" uniqKey="Rossignol P" first="Patrick" last="Rossignol">Patrick Rossignol</name><affiliation wicri:level="4"><nlm:affiliation>From the INSERM UMR 1138 Team 1, Centre de Recherche des Cordeliers, Université Pierre et Marie Curie, Paris, France (A.T., C.A., C.L., S.E.M., N.F., F.J.); NAVARRABIOMED-FUNDACIÓN MIGUEL SERVET, Pamplona, Spain (E.M.-M., N.L.-A.); The Campbell Family Institute for Cancer Research, University Health Network, Toronto, ON, Canada (T.B., T.W.M.); INSERM, Centre d'Investigations Cliniques-Plurithématique 1433, CHU de Nancy, France (R.F., P.R., F.Z., N.L.-A., F.J.); Université de Lorraine, Nancy, France (R.F., P.R., F.Z., N.L.-A., F.J.); and INI-CRCT F-CRIN, Nancy, France (R.F., P.R., F.Z., N.L.-A., F.J.).</nlm:affiliation><orgName type="university">Université Pierre-et-Marie-Curie</orgName><country>France</country><placeName><settlement type="city">Paris</settlement><region type="region" nuts="2">Île-de-France</region></placeName></affiliation></author><author><name sortKey="Zannad, Faiez" sort="Zannad, Faiez" uniqKey="Zannad F" first="Faiez" last="Zannad">Faiez Zannad</name><affiliation wicri:level="4"><nlm:affiliation>From the INSERM UMR 1138 Team 1, Centre de Recherche des Cordeliers, Université Pierre et Marie Curie, Paris, France (A.T., C.A., C.L., S.E.M., N.F., F.J.); NAVARRABIOMED-FUNDACIÓN MIGUEL SERVET, Pamplona, Spain (E.M.-M., N.L.-A.); The Campbell Family Institute for Cancer Research, University Health Network, Toronto, ON, Canada (T.B., T.W.M.); INSERM, Centre d'Investigations Cliniques-Plurithématique 1433, CHU de Nancy, France (R.F., P.R., F.Z., N.L.-A., F.J.); Université de Lorraine, Nancy, France (R.F., P.R., F.Z., N.L.-A., F.J.); and INI-CRCT F-CRIN, Nancy, France (R.F., P.R., F.Z., N.L.-A., F.J.).</nlm:affiliation><orgName type="university">Université Pierre-et-Marie-Curie</orgName><country>France</country><placeName><settlement type="city">Paris</settlement><region type="region" nuts="2">Île-de-France</region></placeName></affiliation></author><author><name sortKey="L Pez Andres, Natalia" sort="L Pez Andres, Natalia" uniqKey="L Pez Andres N" first="Natalia" last="L Pez-Andrés">Natalia L Pez-Andrés</name><affiliation wicri:level="4"><nlm:affiliation>From the INSERM UMR 1138 Team 1, Centre de Recherche des Cordeliers, Université Pierre et Marie Curie, Paris, France (A.T., C.A., C.L., S.E.M., N.F., F.J.); NAVARRABIOMED-FUNDACIÓN MIGUEL SERVET, Pamplona, Spain (E.M.-M., N.L.-A.); The Campbell Family Institute for Cancer Research, University Health Network, Toronto, ON, Canada (T.B., T.W.M.); INSERM, Centre d'Investigations Cliniques-Plurithématique 1433, CHU de Nancy, France (R.F., P.R., F.Z., N.L.-A., F.J.); Université de Lorraine, Nancy, France (R.F., P.R., F.Z., N.L.-A., F.J.); and INI-CRCT F-CRIN, Nancy, France (R.F., P.R., F.Z., N.L.-A., F.J.).</nlm:affiliation><orgName type="university">Université Pierre-et-Marie-Curie</orgName><country>France</country><placeName><settlement type="city">Paris</settlement><region type="region" nuts="2">Île-de-France</region></placeName></affiliation></author><author><name sortKey="Jaisser, Frederic" sort="Jaisser, Frederic" uniqKey="Jaisser F" first="Frédéric" last="Jaisser">Frédéric Jaisser</name><affiliation wicri:level="1"><nlm:affiliation>From the INSERM UMR 1138 Team 1, Centre de Recherche des Cordeliers, Université Pierre et Marie Curie, Paris, France (A.T., C.A., C.L., S.E.M., N.F., F.J.); NAVARRABIOMED-FUNDACIÓN MIGUEL SERVET, Pamplona, Spain (E.M.-M., N.L.-A.); The Campbell Family Institute for Cancer Research, University Health Network, Toronto, ON, Canada (T.B., T.W.M.); INSERM, Centre d'Investigations Cliniques-Plurithématique 1433, CHU de Nancy, France (R.F., P.R., F.Z., N.L.-A., F.J.); Université de Lorraine, Nancy, France (R.F., P.R., F.Z., N.L.-A., F.J.); and INI-CRCT F-CRIN, Nancy, France (R.F., P.R., F.Z., N.L.-A., F.J.). frederic.jaisser@inserm.fr.</nlm:affiliation><country wicri:rule="url">France</country></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="RBID">pubmed:25987661</idno><idno type="pmid">25987661</idno><idno type="doi">10.1161/HYPERTENSIONAHA.115.05431</idno><idno type="wicri:Area/PubMed/Corpus">000053</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000053</idno><idno type="wicri:Area/PubMed/Curation">000053</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000053</idno><idno type="wicri:Area/PubMed/Checkpoint">000044</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000044</idno><idno type="wicri:Area/Ncbi/Merge">000190</idno><idno type="wicri:Area/Ncbi/Curation">000183</idno><idno type="wicri:Area/Ncbi/Checkpoint">000183</idno><idno type="wicri:Area/Main/Merge">000743</idno><idno type="wicri:Area/Main/Curation">000754</idno><idno type="wicri:Area/Main/Exploration">000754</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Neutrophil Gelatinase-Associated Lipocalin, a Novel Mineralocorticoid Biotarget, Mediates Vascular Profibrotic Effects of Mineralocorticoids.</title><author><name sortKey="Tarjus, Antoine" sort="Tarjus, Antoine" uniqKey="Tarjus A" first="Antoine" last="Tarjus">Antoine Tarjus</name><affiliation wicri:level="4"><nlm:affiliation>From the INSERM UMR 1138 Team 1, Centre de Recherche des Cordeliers, Université Pierre et Marie Curie, Paris, France (A.T., C.A., C.L., S.E.M., N.F., F.J.); NAVARRABIOMED-FUNDACIÓN MIGUEL SERVET, Pamplona, Spain (E.M.-M., N.L.-A.); The Campbell Family Institute for Cancer Research, University Health Network, Toronto, ON, Canada (T.B., T.W.M.); INSERM, Centre d'Investigations Cliniques-Plurithématique 1433, CHU de Nancy, France (R.F., P.R., F.Z., N.L.-A., F.J.); Université de Lorraine, Nancy, France (R.F., P.R., F.Z., N.L.-A., F.J.); and INI-CRCT F-CRIN, Nancy, France (R.F., P.R., F.Z., N.L.-A., F.J.).</nlm:affiliation><orgName type="university">Université Pierre-et-Marie-Curie</orgName><country>France</country><placeName><settlement type="city">Paris</settlement><region type="region" nuts="2">Île-de-France</region></placeName></affiliation></author><author><name sortKey="Martinez Martinez, Ernesto" sort="Martinez Martinez, Ernesto" uniqKey="Martinez Martinez E" first="Ernesto" last="Martínez-Martínez">Ernesto Martínez-Martínez</name><affiliation wicri:level="4"><nlm:affiliation>From the INSERM UMR 1138 Team 1, Centre de Recherche des Cordeliers, Université Pierre et Marie Curie, Paris, France (A.T., C.A., C.L., S.E.M., N.F., F.J.); NAVARRABIOMED-FUNDACIÓN MIGUEL SERVET, Pamplona, Spain (E.M.-M., N.L.-A.); The Campbell Family Institute for Cancer Research, University Health Network, Toronto, ON, Canada (T.B., T.W.M.); INSERM, Centre d'Investigations Cliniques-Plurithématique 1433, CHU de Nancy, France (R.F., P.R., F.Z., N.L.-A., F.J.); Université de Lorraine, Nancy, France (R.F., P.R., F.Z., N.L.-A., F.J.); and INI-CRCT F-CRIN, Nancy, France (R.F., P.R., F.Z., N.L.-A., F.J.).</nlm:affiliation><orgName type="university">Université Pierre-et-Marie-Curie</orgName><country>France</country><placeName><settlement type="city">Paris</settlement><region type="region" nuts="2">Île-de-France</region></placeName></affiliation></author><author><name sortKey="Amador, Cristian" sort="Amador, Cristian" uniqKey="Amador C" first="Cristian" last="Amador">Cristian Amador</name><affiliation wicri:level="4"><nlm:affiliation>From the INSERM UMR 1138 Team 1, Centre de Recherche des Cordeliers, Université Pierre et Marie Curie, Paris, France (A.T., C.A., C.L., S.E.M., N.F., F.J.); NAVARRABIOMED-FUNDACIÓN MIGUEL SERVET, Pamplona, Spain (E.M.-M., N.L.-A.); The Campbell Family Institute for Cancer Research, University Health Network, Toronto, ON, Canada (T.B., T.W.M.); INSERM, Centre d'Investigations Cliniques-Plurithématique 1433, CHU de Nancy, France (R.F., P.R., F.Z., N.L.-A., F.J.); Université de Lorraine, Nancy, France (R.F., P.R., F.Z., N.L.-A., F.J.); and INI-CRCT F-CRIN, Nancy, France (R.F., P.R., F.Z., N.L.-A., F.J.).</nlm:affiliation><orgName type="university">Université Pierre-et-Marie-Curie</orgName><country>France</country><placeName><settlement type="city">Paris</settlement><region type="region" nuts="2">Île-de-France</region></placeName></affiliation></author><author><name sortKey="Latouche, Celine" sort="Latouche, Celine" uniqKey="Latouche C" first="Céline" last="Latouche">Céline Latouche</name><affiliation wicri:level="4"><nlm:affiliation>From the INSERM UMR 1138 Team 1, Centre de Recherche des Cordeliers, Université Pierre et Marie Curie, Paris, France (A.T., C.A., C.L., S.E.M., N.F., F.J.); NAVARRABIOMED-FUNDACIÓN MIGUEL SERVET, Pamplona, Spain (E.M.-M., N.L.-A.); The Campbell Family Institute for Cancer Research, University Health Network, Toronto, ON, Canada (T.B., T.W.M.); INSERM, Centre d'Investigations Cliniques-Plurithématique 1433, CHU de Nancy, France (R.F., P.R., F.Z., N.L.-A., F.J.); Université de Lorraine, Nancy, France (R.F., P.R., F.Z., N.L.-A., F.J.); and INI-CRCT F-CRIN, Nancy, France (R.F., P.R., F.Z., N.L.-A., F.J.).</nlm:affiliation><orgName type="university">Université Pierre-et-Marie-Curie</orgName><country>France</country><placeName><settlement type="city">Paris</settlement><region type="region" nuts="2">Île-de-France</region></placeName></affiliation></author><author><name sortKey="El Moghrabi, Soumaya" sort="El Moghrabi, Soumaya" uniqKey="El Moghrabi S" first="Soumaya" last="El Moghrabi">Soumaya El Moghrabi</name><affiliation wicri:level="4"><nlm:affiliation>From the INSERM UMR 1138 Team 1, Centre de Recherche des Cordeliers, Université Pierre et Marie Curie, Paris, France (A.T., C.A., C.L., S.E.M., N.F., F.J.); NAVARRABIOMED-FUNDACIÓN MIGUEL SERVET, Pamplona, Spain (E.M.-M., N.L.-A.); The Campbell Family Institute for Cancer Research, University Health Network, Toronto, ON, Canada (T.B., T.W.M.); INSERM, Centre d'Investigations Cliniques-Plurithématique 1433, CHU de Nancy, France (R.F., P.R., F.Z., N.L.-A., F.J.); Université de Lorraine, Nancy, France (R.F., P.R., F.Z., N.L.-A., F.J.); and INI-CRCT F-CRIN, Nancy, France (R.F., P.R., F.Z., N.L.-A., F.J.).</nlm:affiliation><orgName type="university">Université Pierre-et-Marie-Curie</orgName><country>France</country><placeName><settlement type="city">Paris</settlement><region type="region" nuts="2">Île-de-France</region></placeName></affiliation></author><author><name sortKey="Berger, Thorsten" sort="Berger, Thorsten" uniqKey="Berger T" first="Thorsten" last="Berger">Thorsten Berger</name><affiliation wicri:level="4"><nlm:affiliation>From the INSERM UMR 1138 Team 1, Centre de Recherche des Cordeliers, Université Pierre et Marie Curie, Paris, France (A.T., C.A., C.L., S.E.M., N.F., F.J.); NAVARRABIOMED-FUNDACIÓN MIGUEL SERVET, Pamplona, Spain (E.M.-M., N.L.-A.); The Campbell Family Institute for Cancer Research, University Health Network, Toronto, ON, Canada (T.B., T.W.M.); INSERM, Centre d'Investigations Cliniques-Plurithématique 1433, CHU de Nancy, France (R.F., P.R., F.Z., N.L.-A., F.J.); Université de Lorraine, Nancy, France (R.F., P.R., F.Z., N.L.-A., F.J.); and INI-CRCT F-CRIN, Nancy, France (R.F., P.R., F.Z., N.L.-A., F.J.).</nlm:affiliation><orgName type="university">Université Pierre-et-Marie-Curie</orgName><country>France</country><placeName><settlement type="city">Paris</settlement><region type="region" nuts="2">Île-de-France</region></placeName></affiliation></author><author><name sortKey="Mak, Tak W" sort="Mak, Tak W" uniqKey="Mak T" first="Tak W" last="Mak">Tak W. Mak</name><affiliation wicri:level="4"><nlm:affiliation>From the INSERM UMR 1138 Team 1, Centre de Recherche des Cordeliers, Université Pierre et Marie Curie, Paris, France (A.T., C.A., C.L., S.E.M., N.F., F.J.); NAVARRABIOMED-FUNDACIÓN MIGUEL SERVET, Pamplona, Spain (E.M.-M., N.L.-A.); The Campbell Family Institute for Cancer Research, University Health Network, Toronto, ON, Canada (T.B., T.W.M.); INSERM, Centre d'Investigations Cliniques-Plurithématique 1433, CHU de Nancy, France (R.F., P.R., F.Z., N.L.-A., F.J.); Université de Lorraine, Nancy, France (R.F., P.R., F.Z., N.L.-A., F.J.); and INI-CRCT F-CRIN, Nancy, France (R.F., P.R., F.Z., N.L.-A., F.J.).</nlm:affiliation><orgName type="university">Université Pierre-et-Marie-Curie</orgName><country>France</country><placeName><settlement type="city">Paris</settlement><region type="region" nuts="2">Île-de-France</region></placeName></affiliation></author><author><name sortKey="Fay, Renaud" sort="Fay, Renaud" uniqKey="Fay R" first="Renaud" last="Fay">Renaud Fay</name><affiliation wicri:level="4"><nlm:affiliation>From the INSERM UMR 1138 Team 1, Centre de Recherche des Cordeliers, Université Pierre et Marie Curie, Paris, France (A.T., C.A., C.L., S.E.M., N.F., F.J.); NAVARRABIOMED-FUNDACIÓN MIGUEL SERVET, Pamplona, Spain (E.M.-M., N.L.-A.); The Campbell Family Institute for Cancer Research, University Health Network, Toronto, ON, Canada (T.B., T.W.M.); INSERM, Centre d'Investigations Cliniques-Plurithématique 1433, CHU de Nancy, France (R.F., P.R., F.Z., N.L.-A., F.J.); Université de Lorraine, Nancy, France (R.F., P.R., F.Z., N.L.-A., F.J.); and INI-CRCT F-CRIN, Nancy, France (R.F., P.R., F.Z., N.L.-A., F.J.).</nlm:affiliation><orgName type="university">Université Pierre-et-Marie-Curie</orgName><country>France</country><placeName><settlement type="city">Paris</settlement><region type="region" nuts="2">Île-de-France</region></placeName></affiliation></author><author><name sortKey="Farman, Nicolette" sort="Farman, Nicolette" uniqKey="Farman N" first="Nicolette" last="Farman">Nicolette Farman</name><affiliation wicri:level="4"><nlm:affiliation>From the INSERM UMR 1138 Team 1, Centre de Recherche des Cordeliers, Université Pierre et Marie Curie, Paris, France (A.T., C.A., C.L., S.E.M., N.F., F.J.); NAVARRABIOMED-FUNDACIÓN MIGUEL SERVET, Pamplona, Spain (E.M.-M., N.L.-A.); The Campbell Family Institute for Cancer Research, University Health Network, Toronto, ON, Canada (T.B., T.W.M.); INSERM, Centre d'Investigations Cliniques-Plurithématique 1433, CHU de Nancy, France (R.F., P.R., F.Z., N.L.-A., F.J.); Université de Lorraine, Nancy, France (R.F., P.R., F.Z., N.L.-A., F.J.); and INI-CRCT F-CRIN, Nancy, France (R.F., P.R., F.Z., N.L.-A., F.J.).</nlm:affiliation><orgName type="university">Université Pierre-et-Marie-Curie</orgName><country>France</country><placeName><settlement type="city">Paris</settlement><region type="region" nuts="2">Île-de-France</region></placeName></affiliation></author><author><name sortKey="Rossignol, Patrick" sort="Rossignol, Patrick" uniqKey="Rossignol P" first="Patrick" last="Rossignol">Patrick Rossignol</name><affiliation wicri:level="4"><nlm:affiliation>From the INSERM UMR 1138 Team 1, Centre de Recherche des Cordeliers, Université Pierre et Marie Curie, Paris, France (A.T., C.A., C.L., S.E.M., N.F., F.J.); NAVARRABIOMED-FUNDACIÓN MIGUEL SERVET, Pamplona, Spain (E.M.-M., N.L.-A.); The Campbell Family Institute for Cancer Research, University Health Network, Toronto, ON, Canada (T.B., T.W.M.); INSERM, Centre d'Investigations Cliniques-Plurithématique 1433, CHU de Nancy, France (R.F., P.R., F.Z., N.L.-A., F.J.); Université de Lorraine, Nancy, France (R.F., P.R., F.Z., N.L.-A., F.J.); and INI-CRCT F-CRIN, Nancy, France (R.F., P.R., F.Z., N.L.-A., F.J.).</nlm:affiliation><orgName type="university">Université Pierre-et-Marie-Curie</orgName><country>France</country><placeName><settlement type="city">Paris</settlement><region type="region" nuts="2">Île-de-France</region></placeName></affiliation></author><author><name sortKey="Zannad, Faiez" sort="Zannad, Faiez" uniqKey="Zannad F" first="Faiez" last="Zannad">Faiez Zannad</name><affiliation wicri:level="4"><nlm:affiliation>From the INSERM UMR 1138 Team 1, Centre de Recherche des Cordeliers, Université Pierre et Marie Curie, Paris, France (A.T., C.A., C.L., S.E.M., N.F., F.J.); NAVARRABIOMED-FUNDACIÓN MIGUEL SERVET, Pamplona, Spain (E.M.-M., N.L.-A.); The Campbell Family Institute for Cancer Research, University Health Network, Toronto, ON, Canada (T.B., T.W.M.); INSERM, Centre d'Investigations Cliniques-Plurithématique 1433, CHU de Nancy, France (R.F., P.R., F.Z., N.L.-A., F.J.); Université de Lorraine, Nancy, France (R.F., P.R., F.Z., N.L.-A., F.J.); and INI-CRCT F-CRIN, Nancy, France (R.F., P.R., F.Z., N.L.-A., F.J.).</nlm:affiliation><orgName type="university">Université Pierre-et-Marie-Curie</orgName><country>France</country><placeName><settlement type="city">Paris</settlement><region type="region" nuts="2">Île-de-France</region></placeName></affiliation></author><author><name sortKey="L Pez Andres, Natalia" sort="L Pez Andres, Natalia" uniqKey="L Pez Andres N" first="Natalia" last="L Pez-Andrés">Natalia L Pez-Andrés</name><affiliation wicri:level="4"><nlm:affiliation>From the INSERM UMR 1138 Team 1, Centre de Recherche des Cordeliers, Université Pierre et Marie Curie, Paris, France (A.T., C.A., C.L., S.E.M., N.F., F.J.); NAVARRABIOMED-FUNDACIÓN MIGUEL SERVET, Pamplona, Spain (E.M.-M., N.L.-A.); The Campbell Family Institute for Cancer Research, University Health Network, Toronto, ON, Canada (T.B., T.W.M.); INSERM, Centre d'Investigations Cliniques-Plurithématique 1433, CHU de Nancy, France (R.F., P.R., F.Z., N.L.-A., F.J.); Université de Lorraine, Nancy, France (R.F., P.R., F.Z., N.L.-A., F.J.); and INI-CRCT F-CRIN, Nancy, France (R.F., P.R., F.Z., N.L.-A., F.J.).</nlm:affiliation><orgName type="university">Université Pierre-et-Marie-Curie</orgName><country>France</country><placeName><settlement type="city">Paris</settlement><region type="region" nuts="2">Île-de-France</region></placeName></affiliation></author><author><name sortKey="Jaisser, Frederic" sort="Jaisser, Frederic" uniqKey="Jaisser F" first="Frédéric" last="Jaisser">Frédéric Jaisser</name><affiliation wicri:level="1"><nlm:affiliation>From the INSERM UMR 1138 Team 1, Centre de Recherche des Cordeliers, Université Pierre et Marie Curie, Paris, France (A.T., C.A., C.L., S.E.M., N.F., F.J.); NAVARRABIOMED-FUNDACIÓN MIGUEL SERVET, Pamplona, Spain (E.M.-M., N.L.-A.); The Campbell Family Institute for Cancer Research, University Health Network, Toronto, ON, Canada (T.B., T.W.M.); INSERM, Centre d'Investigations Cliniques-Plurithématique 1433, CHU de Nancy, France (R.F., P.R., F.Z., N.L.-A., F.J.); Université de Lorraine, Nancy, France (R.F., P.R., F.Z., N.L.-A., F.J.); and INI-CRCT F-CRIN, Nancy, France (R.F., P.R., F.Z., N.L.-A., F.J.). frederic.jaisser@inserm.fr.</nlm:affiliation><country wicri:rule="url">France</country></affiliation></author></analytic><series><title level="j">Hypertension</title><idno type="eISSN">1524-4563</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Acute-Phase Proteins (deficiency)</term><term>Acute-Phase Proteins (genetics)</term><term>Acute-Phase Proteins (pharmacology)</term><term>Acute-Phase Proteins (physiology)</term><term>Aldosterone (blood)</term><term>Aldosterone (toxicity)</term><term>Animals</term><term>Aorta (drug effects)</term><term>Aorta (pathology)</term><term>Cardiomyopathy, Hypertrophic (chemically induced)</term><term>Cardiomyopathy, Hypertrophic (physiopathology)</term><term>Cells, Cultured</term><term>Cytokines (biosynthesis)</term><term>Cytokines (genetics)</term><term>Female</term><term>Fibroblasts</term><term>Fibrosis</term><term>Galectin 3 (biosynthesis)</term><term>Galectin 3 (blood)</term><term>Galectin 3 (genetics)</term><term>Humans</term><term>Hypertension (physiopathology)</term><term>Hypertrophy</term><term>Kidney (pathology)</term><term>Lipocalins (blood)</term><term>Lipocalins (genetics)</term><term>Lipocalins (pharmacology)</term><term>Lipocalins (physiology)</term><term>Male</term><term>Mice</term><term>Myocardium (cytology)</term><term>Myocardium (metabolism)</term><term>Myocytes, Smooth Muscle (drug effects)</term><term>Myocytes, Smooth Muscle (physiology)</term><term>Nephrectomy (adverse effects)</term><term>Obesity, Abdominal (blood)</term><term>Obesity, Abdominal (physiopathology)</term><term>Oncogene Proteins (deficiency)</term><term>Oncogene Proteins (genetics)</term><term>Oncogene Proteins (physiology)</term><term>Peptide Fragments (blood)</term><term>Procollagen (blood)</term><term>Proto-Oncogene Proteins (blood)</term><term>Proto-Oncogene Proteins (pharmacology)</term><term>Proto-Oncogene Proteins (physiology)</term><term>Rats</term><term>Recombinant Proteins (pharmacology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Aldostérone (sang)</term><term>Aldostérone (toxicité)</term><term>Animaux</term><term>Aorte ()</term><term>Aorte (anatomopathologie)</term><term>Cardiomyopathie hypertrophique ()</term><term>Cardiomyopathie hypertrophique (physiopathologie)</term><term>Cellules cultivées</term><term>Cytokines (biosynthèse)</term><term>Cytokines (génétique)</term><term>Femelle</term><term>Fibroblastes</term><term>Fibrose</term><term>Fragments peptidiques (sang)</term><term>Galectine -3 (biosynthèse)</term><term>Galectine -3 (génétique)</term><term>Galectine -3 (sang)</term><term>Humains</term><term>Hypertension artérielle (physiopathologie)</term><term>Hypertrophie</term><term>Lipocalines (génétique)</term><term>Lipocalines (pharmacologie)</term><term>Lipocalines (physiologie)</term><term>Lipocalines (sang)</term><term>Myocarde (cytologie)</term><term>Myocarde (métabolisme)</term><term>Myocytes du muscle lisse ()</term><term>Myocytes du muscle lisse (physiologie)</term><term>Mâle</term><term>Néphrectomie (effets indésirables)</term><term>Obésité abdominale (physiopathologie)</term><term>Obésité abdominale (sang)</term><term>Procollagène (sang)</term><term>Protéine de la phase aigüe (déficit)</term><term>Protéine de la phase aigüe (génétique)</term><term>Protéine de la phase aigüe (pharmacologie)</term><term>Protéine de la phase aigüe (physiologie)</term><term>Protéines oncogènes (déficit)</term><term>Protéines oncogènes (génétique)</term><term>Protéines oncogènes (physiologie)</term><term>Protéines proto-oncogènes (pharmacologie)</term><term>Protéines proto-oncogènes (physiologie)</term><term>Protéines proto-oncogènes (sang)</term><term>Protéines recombinantes (pharmacologie)</term><term>Rats</term><term>Rein (anatomopathologie)</term><term>Souris</term></keywords><keywords scheme="MESH" type="chemical" qualifier="biosynthesis" xml:lang="en"><term>Cytokines</term><term>Galectin 3</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Aldosterone</term><term>Galectin 3</term><term>Lipocalins</term><term>Peptide Fragments</term><term>Procollagen</term><term>Proto-Oncogene Proteins</term></keywords><keywords scheme="MESH" type="chemical" qualifier="deficiency" xml:lang="en"><term>Acute-Phase Proteins</term><term>Oncogene Proteins</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Acute-Phase Proteins</term><term>Cytokines</term><term>Galectin 3</term><term>Lipocalins</term><term>Oncogene Proteins</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Acute-Phase Proteins</term><term>Lipocalins</term><term>Proto-Oncogene Proteins</term><term>Recombinant Proteins</term></keywords><keywords scheme="MESH" type="chemical" qualifier="physiology" xml:lang="en"><term>Acute-Phase Proteins</term><term>Lipocalins</term><term>Oncogene Proteins</term><term>Proto-Oncogene Proteins</term></keywords><keywords scheme="MESH" type="chemical" qualifier="toxicity" xml:lang="en"><term>Aldosterone</term></keywords><keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Nephrectomy</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Aorte</term><term>Rein</term></keywords><keywords scheme="MESH" qualifier="biosynthèse" xml:lang="fr"><term>Cytokines</term><term>Galectine -3</term></keywords><keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>Obesity, Abdominal</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Cardiomyopathy, Hypertrophic</term></keywords><keywords scheme="MESH" qualifier="cytologie" xml:lang="fr"><term>Myocarde</term></keywords><keywords scheme="MESH" qualifier="cytology" xml:lang="en"><term>Myocardium</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Aorta</term><term>Myocytes, Smooth Muscle</term></keywords><keywords scheme="MESH" qualifier="déficit" xml:lang="fr"><term>Protéine de la phase aigüe</term><term>Protéines oncogènes</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Néphrectomie</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Cytokines</term><term>Galectine -3</term><term>Lipocalines</term><term>Protéine de la phase aigüe</term><term>Protéines oncogènes</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Myocardium</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Myocarde</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Aorta</term><term>Kidney</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Lipocalines</term><term>Protéine de la phase aigüe</term><term>Protéines proto-oncogènes</term><term>Protéines recombinantes</term></keywords><keywords scheme="MESH" qualifier="physiologie" xml:lang="fr"><term>Lipocalines</term><term>Myocytes du muscle lisse</term><term>Protéine de la phase aigüe</term><term>Protéines oncogènes</term><term>Protéines proto-oncogènes</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Myocytes, Smooth Muscle</term></keywords><keywords scheme="MESH" qualifier="physiopathologie" xml:lang="fr"><term>Cardiomyopathie hypertrophique</term><term>Hypertension artérielle</term><term>Obésité abdominale</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Cardiomyopathy, Hypertrophic</term><term>Hypertension</term><term>Obesity, Abdominal</term></keywords><keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Aldostérone</term><term>Fragments peptidiques</term><term>Galectine -3</term><term>Lipocalines</term><term>Obésité abdominale</term><term>Procollagène</term><term>Protéines proto-oncogènes</term></keywords><keywords scheme="MESH" qualifier="toxicité" xml:lang="fr"><term>Aldostérone</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Cells, Cultured</term><term>Female</term><term>Fibroblasts</term><term>Fibrosis</term><term>Humans</term><term>Hypertrophy</term><term>Male</term><term>Mice</term><term>Rats</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Aorte</term><term>Cardiomyopathie hypertrophique</term><term>Cellules cultivées</term><term>Femelle</term><term>Fibroblastes</term><term>Fibrose</term><term>Humains</term><term>Hypertrophie</term><term>Myocytes du muscle lisse</term><term>Mâle</term><term>Rats</term><term>Souris</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Activation of the mineralocorticoid receptor has been shown to be deleterious in cardiovascular diseases (CVDs). We have recently shown that lipocalin 2 (Lcn2), or neutrophil gelatinase-associated lipocalin (NGAL), is a primary target of aldosterone/mineralocorticoid receptor in the cardiovascular system. Lcn2 is a circulating protein, which binds matrix metalloproteinase 9 and modulates its stability. We hypothesized that Lcn2 could be a mediator of aldosterone/mineralocorticoid receptor profibrotic effects in the cardiovascular system. Correlations between aldosterone and profibrotic markers, such as procollagen type I N-terminal peptide, were investigated in healthy subjects and subjects with abdominal obesity. The implication of Lcn2 in the mineralocorticoid pathway was studied using Lcn2 knockout mice subjected to a nephrectomy/aldosterone/salt (NAS) challenge for 4 weeks. In human subjects, NGAL/matrix metalloproteinase 9 was positively correlated with plasma aldosterone and fibrosis biomarkers. In mice, loss of Lcn2 prevented the NAS-induced increase of plasma procollagen type I N-terminal peptide, as well as the increase of collagen fibers deposition and collagen I expression in the coronary vessels and the aorta. The lack of Lcn2 also blunted the NAS-induced increase in systolic blood pressure. Ex vivo, treatment of human fibroblasts with recombinant Lcn2 induced the expression of collagen I and the profibrotic galectin-3 and cardiotrophin-1 molecules. Our results showed that Lcn2 plays a key role in aldosterone/mineralocorticoid receptor-mediated vascular fibrosis. The clinical data indicate that this may translate in human patients. Lcn2 is, therefore, a new biotarget in cardiovascular fibrosis induced by mineralocorticoid activation.</div></front></TEI><affiliations><list><country><li>France</li></country><region><li>Île-de-France</li></region><settlement><li>Paris</li></settlement><orgName><li>Université Pierre-et-Marie-Curie</li></orgName></list><tree><country name="France"><region name="Île-de-France"><name sortKey="Tarjus, Antoine" sort="Tarjus, Antoine" uniqKey="Tarjus A" first="Antoine" last="Tarjus">Antoine Tarjus</name></region><name sortKey="Amador, Cristian" sort="Amador, Cristian" uniqKey="Amador C" first="Cristian" last="Amador">Cristian Amador</name><name sortKey="Berger, Thorsten" sort="Berger, Thorsten" uniqKey="Berger T" first="Thorsten" last="Berger">Thorsten Berger</name><name sortKey="El Moghrabi, Soumaya" sort="El Moghrabi, Soumaya" uniqKey="El Moghrabi S" first="Soumaya" last="El Moghrabi">Soumaya El Moghrabi</name><name sortKey="Farman, Nicolette" sort="Farman, Nicolette" uniqKey="Farman N" first="Nicolette" last="Farman">Nicolette Farman</name><name sortKey="Fay, Renaud" sort="Fay, Renaud" uniqKey="Fay R" first="Renaud" last="Fay">Renaud Fay</name><name sortKey="Jaisser, Frederic" sort="Jaisser, Frederic" uniqKey="Jaisser F" first="Frédéric" last="Jaisser">Frédéric Jaisser</name><name sortKey="L Pez Andres, Natalia" sort="L Pez Andres, Natalia" uniqKey="L Pez Andres N" first="Natalia" last="L Pez-Andrés">Natalia L Pez-Andrés</name><name sortKey="Latouche, Celine" sort="Latouche, Celine" uniqKey="Latouche C" first="Céline" last="Latouche">Céline Latouche</name><name sortKey="Mak, Tak W" sort="Mak, Tak W" uniqKey="Mak T" first="Tak W" last="Mak">Tak W. Mak</name><name sortKey="Martinez Martinez, Ernesto" sort="Martinez Martinez, Ernesto" uniqKey="Martinez Martinez E" first="Ernesto" last="Martínez-Martínez">Ernesto Martínez-Martínez</name><name sortKey="Rossignol, Patrick" sort="Rossignol, Patrick" uniqKey="Rossignol P" first="Patrick" last="Rossignol">Patrick Rossignol</name><name sortKey="Zannad, Faiez" sort="Zannad, Faiez" uniqKey="Zannad F" first="Faiez" last="Zannad">Faiez Zannad</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Lorraine/explor/InforLorV4/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000754 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000754 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Lorraine
|area= InforLorV4
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:25987661
|texte= Neutrophil Gelatinase-Associated Lipocalin, a Novel Mineralocorticoid Biotarget, Mediates Vascular Profibrotic Effects of Mineralocorticoids.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:25987661" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a InforLorV4
| This area was generated with Dilib version V0.6.33. |  |